- TRADE NAMES: Inflectra (Celltrion); Remicade (Centocor); Remsima (Celltrion); Renflexis (Samsung Bioepsis)
- INDICATIONS: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis
- SYNONYM: CT-P13 is biosimilar infliximab
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Antipsoriatic agent, Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Cytokine inhibitor, Disease-modifying antirheumatic drug (DMARD), Monoclonal antibody
- HALF-LIFE: 8–10 days
TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
Contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
Infliximab-dyyb (Inflectra) is biosimilar to Infliximab (Remicade). Approved 04/05/2016
Infliximab-abda (Renflexis) is biosimilar to Infliximab (Remicade). Approved 04/21/2017
Infliximab-qbtx (Ixifi) is biosimilar to Infliximab (Remicade). Approved 12/13/2017
Infliximab-axxq (Avsola) is biosimilar to Infliximab (Remicade). Approved 12/06/2019
Infliximab-dyyb (Zymfentra) is biosimilar to Infliximab. Approved 10/20/2023
SERIOUS INFECTIONS and MALIGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
DRUG REVIEW ARTICLE
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of infliximab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/06/2025
